Insider · CIK 0001322927

Ahrens Brenton Karl

Reports to the SEC for 4 companies · WESTPORT, CT

sec.gov

Transactions

Companies

Filings

CIK

0001322927

Forms 4 and 5

Insider transactions

45 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-12-23	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+29.1K sh	$0.81	+$23.6K	29,125
2022-09-25	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+14.8K sh	$1.59	+$23.6K	14,838
2022-09-20	ITRMIterum Therapeutics plcS Sale	Director	SSale	−7,246 sh	$1.78	−$12.9K	0
2022-09-19	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$1.77	−$26.5K	7,246
2022-09-16	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$1.90	−$28.5K	22,246
2022-09-15	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$2.02	−$30.3K	37,246
2022-09-14	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$2.10	−$31.5K	52,246
2022-09-13	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$2.14	−$32.1K	67,246
2022-09-12	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$2.31	−$34.6K	82,246
2022-09-09	ITRMIterum Therapeutics plcS Sale	Director	SSale	−15K sh	$2.32	−$34.7K	97,246
2022-09-08	ITRMIterum Therapeutics plcS Sale	Director	SSale	−3,298 sh	$2.26	−$7,465.023	112,246
2022-06-25	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+113K sh	—	—	113,276
2022-06-15	ITRMIterum Therapeutics plc · Share Option (Right to Buy)A Award	Director	AAward	+647K sh	—	—	647,059
2022-03-25	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+47.4K sh	—	—	47,436
2021-06-23	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+64.7K sh	—	—	64,706
2020-01-21	ITRMIterum Therapeutics plc · 6.500% Exchangeable Senior Subordinated Note due 2025A Award	Director	AAward	—	$2000000.00	—	—
2019-06-13	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director	AAward	+19.7K sh	—	—	19,671
2019-05-24	ITRMIterum Therapeutics plcM Exercise/Conversion	Director	MExercise/Conversion	+6,154 sh	—	—	6,154
2019-05-24	ITRMIterum Therapeutics plc · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−6,154 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+721K sh	—	—	721,408
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+275K sh	—	—	996,854
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director	CConversion	+230K sh	—	—	1,226,514
2018-05-30	ITRMIterum Therapeutics plcP Purchase	Director	PPurchase	+507K sh	$13.00	+$6.59M	1,733,170
2018-05-30	ITRMIterum Therapeutics plc · Series A Preferred SharesC Conversion	Director	CConversion	−721K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-1 Preferred SharesC Conversion	Director	CConversion	−275K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-2 Preferred SharesC Conversion	Director	CConversion	−230K sh	—	—	0
2018-05-24	ITRMIterum Therapeutics plc · Restricted Stock UnitsA Award	Director	AAward	+6,154 sh	—	—	6,154
2014-11-17	Durata Therapeutics, Inc.U Disposition from Tender	Director, 10% Owner	UDisposition from Tender	−1.9M sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−5,034 sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.Restricted StockD Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−1,216 sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−8,575 sh	—	—	0
2014-08-26	Durata Therapeutics, Inc.M Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	+5,034 sh	$2.08	+$10.5K	5,034
2014-08-26	Durata Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	−6,250 sh	—	—	0
2014-08-26	Durata Therapeutics, Inc.Restricted StockM Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	−1,216 sh	—	—	1,216
2012-07-24	Durata Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.35M sh	—	—	1,346,475
2012-07-24	Durata Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+556K sh	$9.00	+$5M	1,902,030
2012-07-24	Durata Therapeutics, Inc.Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−10.8M sh	—	—	0
2012-02-28	Durata Therapeutics, Inc.Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+6,250 sh	—	—	6,250
2006-04-13	DXCMDEXCOM INC · Non-Qualified Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2005-04-19	DXCMDEXCOM INCC Conversion	Director	CConversion	+1.73M sh	—	—	1,733,941
2005-04-19	DXCMDEXCOM INCC Conversion	Director	CConversion	+1.08M sh	—	—	1,079,075
2005-04-19	DXCMDEXCOM INCC Conversion	Director	CConversion	+281K sh	—	—	280,619
2005-04-19	DXCMDEXCOM INC · Series B Preferred StockC Conversion	Director	CConversion	−3.47M sh	—	—	0
2005-04-19	DXCMDEXCOM INC · Series C Preferred StockC Conversion	Director	CConversion	−2.16M sh	—	—	0
2005-04-19	DXCMDEXCOM INC · Series D Preferred StockC Conversion	Director	CConversion	−561K sh	—	—	0

Recent filings

Accepted (ET)
Dec 284
Ahrens Brenton Karl0001209191-22-062873
SEC(opens sec.gov)
Sep 284
Ahrens Brenton Karl0001209191-22-051422
SEC(opens sec.gov)
Sep 204
Ahrens Brenton Karl0000899243-22-031603
SEC(opens sec.gov)
Sep 154
Ahrens Brenton Karl0000899243-22-031172
SEC(opens sec.gov)
Sep 124
Ahrens Brenton Karl0000899243-22-030853
SEC(opens sec.gov)
Jun 284
Ahrens Brenton Karl0001209191-22-039711
SEC(opens sec.gov)
Jun 174
Ahrens Brenton Karl0001209191-22-037946
SEC(opens sec.gov)
Mar 294
Ahrens Brenton Karl0001209191-22-021543
SEC(opens sec.gov)
Jun 254
Ahrens Brenton Karl0000899243-21-025955
SEC(opens sec.gov)
Jan 234
Ahrens Brenton Karl0000899243-20-001847
SEC(opens sec.gov)
Jun 174
Ahrens Brenton Karl0000899243-19-017206
SEC(opens sec.gov)
May 294
Ahrens Brenton Karl0000899243-19-015012
SEC(opens sec.gov)
May 304
Ahrens Brenton Karl0001209191-18-034204
SEC(opens sec.gov)

Companies

Address

C/O CANAAN PARTNERS 285 RIVERSIDE AVENUE, SUITE 250

WESTPORT, CT, 06880